These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16379015)

  • 1. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
    Zarich SW
    Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance.
    Bethea SW; Nestler JE
    Panminerva Med; 2008 Dec; 50(4):295-304. PubMed ID: 19078870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular risk factors and cognitive decline among elderly male twins.
    Xiong GL; Plassman BL; Helms MJ; Steffens DC
    Neurology; 2006 Nov; 67(9):1586-91. PubMed ID: 17101888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke and the metabolic syndrome in populations: the challenge ahead.
    Cronin S; Kelly PJ
    Stroke; 2009 Jan; 40(1):3-4. PubMed ID: 18927444
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic syndrome.
    Reaven P
    J Insur Med; 2004; 36(2):132-42. PubMed ID: 15301226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges associated with metabolic syndrome.
    Spinler SA
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):209S-217S. PubMed ID: 17125447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic syndrome and its cardiovascular manifestations.
    Sánchez-Torres RJ; Delgado-Osorio H
    Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertension as a part of metabolic cardiovascular syndrome].
    Os I; Hjermann I; Nordby G
    Tidsskr Nor Laegeforen; 1991 Oct; 111(25):3062-4. PubMed ID: 1948918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
    Wyne KL
    Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward an improved diagnosis of the metabolic syndrome other clues to the presence of insulin resistance.
    Cohn GS; Kittleson MM; Blumenthal RS
    Am J Hypertens; 2005 Aug; 18(8):1099-103. PubMed ID: 16109324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome and its components after liver transplantation: incidence, prevalence, risk factors, and implications.
    Anastácio LR; Lima AS; Toulson Davisson Correia MI
    Clin Nutr; 2010 Apr; 29(2):175-9. PubMed ID: 19783330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage.
    Mulé G; Cottone S; Nardi E; Andronico G; Cerasola G
    Minerva Cardioangiol; 2006 Apr; 54(2):173-94. PubMed ID: 16778751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care.
    Lender D; Sysko SK
    Pharmacotherapy; 2006 May; 26(5 Pt 2):3S-12S. PubMed ID: 16637782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.